TGTX BRIUMVI on track for $1B run rate amid pipeline expansion
BRIUMVI is on track for a $1 billion run rate, supported by commercial expansion and a clinical pipeline targeting MS and other indications. SubQ formulation is expected to drive future growth, with patent protection extending to 2042.